Our Team
Principal Investigator
Jun Qi, Ph.D.
Jun received his BS degree from Fudan University in China, obtained his Ph.D. in Chemistry from University of Michigan with Prof. William Roush in 2006, and completed his postdoctoral training at MIT with Prof. Mo Movassaghi in 2009. Both his Ph.D. and postdoctoral studies have been focused on the total synthesis of natural compounds and novel synthetic methodology development. After his postdoctoral training, he led the chemistry effort in Dr. James Bradner's laboratory on developing BET bromodomain inhibitor JQ1 and optimizing this chemistry probe to a human clinical candidate. His study focuses on the design and synthesis of small molecule inhibitors targeting the gene regulation pathway for cancer therapy; and on understanding the roles of epigenetic proteins in cancers.
Email
Jun received his BS degree from Fudan University in China, obtained his Ph.D. in Chemistry from University of Michigan with Prof. William Roush in 2006, and completed his postdoctoral training at MIT with Prof. Mo Movassaghi in 2009. Both his Ph.D. and postdoctoral studies have been focused on the total synthesis of natural compounds and novel synthetic methodology development. After his postdoctoral training, he led the chemistry effort in Dr. James Bradner's laboratory on developing BET bromodomain inhibitor JQ1 and optimizing this chemistry probe to a human clinical candidate. His study focuses on the design and synthesis of small molecule inhibitors targeting the gene regulation pathway for cancer therapy; and on understanding the roles of epigenetic proteins in cancers.
Postdoctoral Fellows
Cheng-Kui Pei, Ph.D.
Cheng-Kui earned his Ph.D. in chemistry at the East China University of Science and Technology under the guidance of Professor Min Shi. His graduate studies focused on the development of new chiral ligands in catalytic asymmetric synthesis and Morita-Baylis-Hillman reaction. He joined the Qi lab in August 2016 and is interested in the rational design of small molecules. Outside of lab he enjoys watching horror movies.
Ph.D. East China University of Science and Technology
B.S. East China University of Science and Technology
Email
Cheng-Kui earned his Ph.D. in chemistry at the East China University of Science and Technology under the guidance of Professor Min Shi. His graduate studies focused on the development of new chiral ligands in catalytic asymmetric synthesis and Morita-Baylis-Hillman reaction. He joined the Qi lab in August 2016 and is interested in the rational design of small molecules. Outside of lab he enjoys watching horror movies.
Ph.D. East China University of Science and Technology
B.S. East China University of Science and Technology
Wai-Lung Ng, Ph.D.
Wai-lung is from Hong Kong, and earned his Ph.D. in organic chemistry at the Chinese University of Hong Kong (CUHK) under the guidance of Professor Tony K. M. Shing. His graduate studies focused on the syntheses of a new class of anti-diabetic agents (SGLT2 inhibitors). In 2013, he researched on transition metal-catalyzed reactions at MIT (as a Fulbright Scholar), then moved to University of Oxford to study on the development of a new chemical strategy for epigenetic proteins.
Ph.D. The Chinese University of Hong Kong
B.Sc. The Chinese University of Hong Kong
Email
Wai-lung is from Hong Kong, and earned his Ph.D. in organic chemistry at the Chinese University of Hong Kong (CUHK) under the guidance of Professor Tony K. M. Shing. His graduate studies focused on the syntheses of a new class of anti-diabetic agents (SGLT2 inhibitors). In 2013, he researched on transition metal-catalyzed reactions at MIT (as a Fulbright Scholar), then moved to University of Oxford to study on the development of a new chemical strategy for epigenetic proteins.
Ph.D. The Chinese University of Hong Kong
B.Sc. The Chinese University of Hong Kong
Lingling Dai, Ph.D.
Lingling completed a joint Ph.D. program from Harvard T.H. Chan School of Public Health and Central South University where she focused on immune-metabolic signaling crosstalk under physiological and pathological conditions. She joined the Qi lab in September 2017. Outside of lab she enjoys skiing and eating chocolate.
Ph.D. Harvard T.H. Chan School of Public Health and Central South University
B.S. Central South University
Email
Lingling completed a joint Ph.D. program from Harvard T.H. Chan School of Public Health and Central South University where she focused on immune-metabolic signaling crosstalk under physiological and pathological conditions. She joined the Qi lab in September 2017. Outside of lab she enjoys skiing and eating chocolate.
Ph.D. Harvard T.H. Chan School of Public Health and Central South University
B.S. Central South University
Deyao Li, Ph.D.
Deyao completed his Ph.D. from Shanghai Institute of Organic Chemistry focusing on the Gold Homogenous catalytic reactions. He then joined Domestic Drug Discovery Unit at WuXi Apptec, where he worked on developing several kinase inhibitors. He joined the Qi lab in October 2018 and is interested in developing small-molecule probes that target epigenetic proteins for cancer therapy. Outside of lab, he likes to cook and drive around Boston.
Ph.D. Shanghai Institute of Organic Chemistry (CAS)
B.S. China Pharmaceutical University
Email
Deyao completed his Ph.D. from Shanghai Institute of Organic Chemistry focusing on the Gold Homogenous catalytic reactions. He then joined Domestic Drug Discovery Unit at WuXi Apptec, where he worked on developing several kinase inhibitors. He joined the Qi lab in October 2018 and is interested in developing small-molecule probes that target epigenetic proteins for cancer therapy. Outside of lab, he likes to cook and drive around Boston.
Ph.D. Shanghai Institute of Organic Chemistry (CAS)
B.S. China Pharmaceutical University
Computational Biologists
Paul M. Park
Paul is from Takoma Park, Maryland, and attended college at Purdue University, where he worked for Professor Stephen Konieczny. His undergraduate research focused on defining key transcription factors related to pancreatic cancer. Paul joined the Qi lab in September 2016. Outside of lab, he enjoys hiking, playing soccer and basketball, and traveling.
B.S. Purdue University
Email
Paul is from Takoma Park, Maryland, and attended college at Purdue University, where he worked for Professor Stephen Konieczny. His undergraduate research focused on defining key transcription factors related to pancreatic cancer. Paul joined the Qi lab in September 2016. Outside of lab, he enjoys hiking, playing soccer and basketball, and traveling.
B.S. Purdue University
Research Technicians
Virangika K. Wimalasena
Virangika is from Wichita, Kansas and earned her B.S. in Biochemistry at The University of Kansas. While at KU, she worked in both Dr. Brian Blagg's lab to evaluate EGCG analogs as anticancer C-terminal Hsp90 inhibitors, and in Dr. Joanna Slusky's lab to determine the specificity of a designed peptide that inhibits antibiotic resistance. Virangika joined the Qi lab in July 2018 and is interested in probing the biological intersection of epigenetics and carcinogenesis using small molecules. Outside of lab, she enjoys James Blake, twitter memes, and the oxford comma.
B.S. The University of Kansas
Email
Virangika is from Wichita, Kansas and earned her B.S. in Biochemistry at The University of Kansas. While at KU, she worked in both Dr. Brian Blagg's lab to evaluate EGCG analogs as anticancer C-terminal Hsp90 inhibitors, and in Dr. Joanna Slusky's lab to determine the specificity of a designed peptide that inhibits antibiotic resistance. Virangika joined the Qi lab in July 2018 and is interested in probing the biological intersection of epigenetics and carcinogenesis using small molecules. Outside of lab, she enjoys James Blake, twitter memes, and the oxford comma.
B.S. The University of Kansas
Alumni
Lei Wu, Ph.D. (08/2016 - 12/2018, Postdoc Fellow)
Senior Scientist at QL Regor
Mousheng Xu, Ph.D. (05/2016, 5 - 11/2017, Bioinformatic Analyst II)
Senior Statistical Geneticist at Booz Allen Hamilton
Jennifer Perry, Ph.D. (01/2016 - 07/2017, Senior Scientist)
Associate Director for the Center of Pediatric Cancer Therapeutics at DFCI
Matthew Lawlor (01/2016 - 09/2017, Bioinformatic Analyst I)
Research Technician at MGH
Nana Kwaku Offei-Addo (08/2016 - 11/2017, Research Technician)
Research Associate at Generation Bio
Michael Xiang (2016, 2017, Summer Intern)
Undergraduate student at Johns Hopkins
Morgan Schwartz (2018, Summer Intern)
Undergraduate student at The University of Vermont
Paula Zoutine (2018, Intern)
Undergraduate student at Boston University
Lei Wu, Ph.D. (08/2016 - 12/2018, Postdoc Fellow)
Senior Scientist at QL Regor
Mousheng Xu, Ph.D. (05/2016, 5 - 11/2017, Bioinformatic Analyst II)
Senior Statistical Geneticist at Booz Allen Hamilton
Jennifer Perry, Ph.D. (01/2016 - 07/2017, Senior Scientist)
Associate Director for the Center of Pediatric Cancer Therapeutics at DFCI
Matthew Lawlor (01/2016 - 09/2017, Bioinformatic Analyst I)
Research Technician at MGH
Nana Kwaku Offei-Addo (08/2016 - 11/2017, Research Technician)
Research Associate at Generation Bio
Michael Xiang (2016, 2017, Summer Intern)
Undergraduate student at Johns Hopkins
Morgan Schwartz (2018, Summer Intern)
Undergraduate student at The University of Vermont
Paula Zoutine (2018, Intern)
Undergraduate student at Boston University